Pharmaceuticals

Relmada Therapeutics

Relmada Therapeutics released FY2026 Q1 earnings on May 12 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.22 (forecast USD -0.195)

Relmada Therapeutics to Release FY2026 Q1 Earnings on May 12 During-Market EST, Forecast EPS USD -0.195

Relmada Therapeutics released FY2025 earnings on March 19 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -1.4535 (forecast USD -1.1475)

Relmada Therapeutics released FY2025 Q4 earnings on March 19 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3251 (forecast USD -0.14)

Relmada Therapeutics to Release FY2025 Q4 Earnings on March 19 After-Market EST, Forecasted Revenue USD 0, EPS USD -0.14

Relmada Therapeutics released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.304 (forecast USD -0.04)

Relmada Therapeutics released FY2025 9 Months earnings on November 13 After-Market EST, actual revenue USD 0, actual EPS USD -1.1787

Relmada Therapeutics to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast EPS -0.04 USD

Relmada Therapeutics released FY2025 Semi-Annual earnings on August 7 After-Market (EST), actual revenue USD 0, actual EPS USD -0.8622

Relmada Therapeutics released FY2025 Q2 earnings on August 7 After-Market EST: Actual Revenue USD 0, Actual EPS USD -0.3 (Forecast EPS USD -0.04)

Relmada Therapeutics to release FY2025 Q2 earnings report on August 7 After-Market EST, forecast EPS USD -0.04

RELMADA THERAPEUTICS Executives Buy Large Amounts of Company Stock

Chief Executive of Relmada Therapeutics Inc. Acquires Company Shares

Relmada Therapeutics released FY2025 Q1 earnings on May 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5774 (forecast USD -0.31)

Relmada Therapeutics records a Q1 net loss of $17.5 million

Relmada Therapeutics Expected to Report Quarterly Loss of 31 Cents Per Share

Relmada Therapeutics to release FY2025 Q1 earnings report on May 12 After-Market EST, forecast EPS USD -0.31

Relmada Therapeutics Inc Expected to Report Q1 2025 Earnings Loss of 31 Cents

Relmada Therapeutics to Present NDV-01 Data at AUA2025

Relmada Therapeutics released FY2024 Q4 earnings on March 27 After-Market (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.6183 USD (forecast -0.7 USD)

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

ABVX

RLMD

SVCO

U.S. stock futures surged over 7% on Wednesday, driven by AI optimism. Marvell Technology shares jumped 11.73% to $324.92 in pre-market trading after NVIDIA CEO Jensen Huang endorsed the company and highlighted a strategic partnership for next-gen AI data center switches. Other notable gainers included Relmada Therapeutics (+15.41%), Eightco Holdings (+13.27%), Abivax (+13.10%), GameStop (+12.61% following strong Q1 earnings and buyback news), Nextav (+12.21%), Rezolute (+11.74%), Silvaco (+10.92%), BitVentures (+10.85%), and AngioDynamics (+9.19%).

- U.S. stock futures saw significant gains, particularly with Nasdaq futures rising over 7.09%, driven by optimism in the artificial intelligence and enterprise hardware sectors.  
- Marvell Technology Inc. shares surged 11.73% to $324.92 after receiving an endorsement from NVIDIA CEO Jensen Huang, following a 32% rally from the previous session.  
- Other notable pre-market movers included Relmada Therapeutics gaining 15.41%, GameStop rising 12.61%, and AngioDynamics up 9.19%, reflecting broad investor interest across multiple sectors.

benzinga_article

Abivax SA

Silvaco

Eightco

NVIDIA

Rezolute

GameStop

Angiodynamics

Marvell Tech

BitVentures

T-Rex 2X Long NVIDIA Daily Target ETF

SPDR S&P Semicon

Direxion Daily NVDA Bear 1X ETF

Invesco PHLX Semiconductor ETF

Spdr Select Tech

VanEck Semiconductor ETF

AXS 1.5X NVDA Bear Daily ETF

Invesco Semiconductors ETF

GraniteShares 2x Short NVDA Daily ETF

First Trust Nasdaq Food & Semicon

ISHRS S&P Glb It

iShares Semiconductor ETF

T-Rex 2X Long GME Daily Target ETF

Direxion Daily NVDA Bull 2X Shares

Direxion Semicon Bull 3X

YieldMax NVDA Option Income Strategy ETF

GraniteShares 2x Long MRVL Daily ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

eBay

NextNav

NVIDIA Corporation

GAMESTOP CORPORATION C/WTS (TO PUR COM) 30/10/2026

NextNav - CW27

Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session

SNGX

NOTV

NOTVQ

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Gainers included Picard Medical (+30.7%), Relmada Therapeutics (+15.41%), and Abivax (+15.17%). Conversely, notable decliners were Inotiv (-40.4%), TransCode Therapeutics (-29.05%), and Soligenix (-19.88%). The report highlights specific percentage changes and market capitalizations for these companies.

Soligenix

Inotiv

INOTIV INC

Picard Medical

Connect Biopharma

QT Imaging

Agape ATP

TransCode Therapeutics

Basel Medical

AIM ImmunoTech

NRX Therapeutics

QT Imaging Holdings, Inc.

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

NRX Pharmaceuticals - CW22

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

ARKG

LABU

SBIO

Relmada Therapeutics (NASDAQ: RLMD) is on track to initiate its Phase 3 RESCUE program for NDV-01 in mid-2026, following positive 12-month Phase 2 data in non-muscle invasive bladder cancer. The company has strengthened its balance sheet through a $160 million private financing. CEO Dr. Sergio Traversa highlighted the promising efficacy data and alignment with the FDA. NDV-01 showed a 95% complete response rate at any time and 76% at 12 months in high-risk patients. The RESCUE program will include two registration pathways, targeting BCG-unresponsive patients and adjuvant therapy after TURBT.

Market Beat

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

Relmada Therapeutics Q1 Earnings Call Highlights

HROW

HROWL

HROWM

Harrow Inc (NASDAQ:HROW) reported Q1 2026 revenues of $44.2 million, with an adjusted EBITDA of -$12.7 million, impacted by an $8 million gross-to-net issue with its product Vivi. The company has expanded its sales force to drive growth and reaffirmed its full-year revenue guidance of $350 million to $365 million, anticipating strong performance in the second half due to new product launches and improved pricing strategies. Demand for core products remains strong, indicating sustainable market share capture and potential for profitable revenue growth.

Harrow

Harrow Health Pref Share HROWL 8.625 04/30/26

Harrow Health Pref Share HROWM 11.875 12/31/27

SPDR Pharmac

Transcript: Harrow Q1 2026 Earnings Conference Call

Earnings Watch

Relmada Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Relmada Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0